<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' xmlns='http://datacite.org/schema/kernel-3' xsi:schemaLocation='http://datacite.org/schema/kernel-3 http://schema.datacite.org/meta/kernel-3/metadata.xsd'>
<identifier identifierType='DOI'>10.3201/eid2103.141343</identifier>
<creators>
<creator>
<creatorName>Gunther, G.</creatorName>
<affiliation>University of Namibia, School of Medicine, Windhoek, Namibia</affiliation>
</creator>
<creator>
<creatorName>Gunther, G.</creatorName>
<affiliation>University of Amsterdam, Țările de Jos (Olanda)</affiliation>
</creator>
<creator>
<creatorName>Alexandru, S.</creatorName>
<affiliation>IMSP Institutul de Ftiziopneumologie „Chiril Draganiuc“, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Alexandru, S.</creatorName>
</creator>
<creator>
<creatorName>Barbuţă, R.</creatorName>
<affiliation>Spitalul Clinic Municipal, Bălţi, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Crudu, V.N.</creatorName>
<affiliation>IMSP Institutul de Ftiziopneumologie „Chiril Draganiuc“, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Cernenco, I.</creatorName>
<affiliation>IMSP Spitalul raional Ialoveni, Moldova, Republica</affiliation>
</creator>
<creator>
<creatorName>Dubceac, V.</creatorName>
<affiliation>Spitalul Clinic Municipal, Bălţi, Moldova, Republica</affiliation>
</creator>
</creators>
<titles>
<title xml:lang='en'>Multidrug-resistant tuberculosis in Europe, 2010-2011</title>
</titles>
<publisher>Instrumentul Bibliometric National</publisher>
<publicationYear>2015</publicationYear>
<relatedIdentifier relatedIdentifierType='ISSN' relationType='IsPartOf'>1080-6040</relatedIdentifier>
<subjects>
<subject>adult</subject>
<subject>Antitubercular Agents</subject>
<subject>comorbidity</subject>
<subject>Cross-Sectional Studies</subject>
<subject>Europe</subject>
<subject>female</subject>
<subject>history</subject>
<subject>21st Century</subject>
<subject>Humans</subject>
<subject>incidence</subject>
<subject>Male</subject>
<subject>Microbial Sensitivity Tests</subject>
<subject>middle aged</subject>
<subject>Mycobacterium tuberculosis</subject>
<subject>Population Surveillance</subject>
<subject>risk factors</subject>
<subject>tuberculosis</subject>
<subject>Multidrug-Resistant</subject>
</subjects>
<dates>
<date dateType='Issued'>2015-03-01</date>
</dates>
<resourceType resourceTypeGeneral='Text'>Journal article</resourceType>
<descriptions>
<description xml:lang='en' descriptionType='Abstract'><p>Drug-resistant Mycobacterium tuberculosis is challenging elimination of tuberculosis (TB). We evaluated risk factors for TB and levels of second-line drug resistance in M. tuberculosis in patients in Europe with multidrug-resistant (MDR) TB. A total of 380 patients with MDR TB and 376 patients with non-MDR TB were enrolled at 23 centers in 16 countries in Europe during 2010-2011. A total of 52.4% of MDR TB patients had never been treated for TB, which suggests primary transmission of MDR M. tuberculosis. At initiation of treatment for MDR TB, 59.7% of M. tuberculosis strains tested were resistant to pyrazinamide, 51.1% were resistant to &gt;1 second-line drug, 26.6% were resistant to second-line injectable drugs, 17.6% were resistant to fuoroquinolones, and 6.8% were extensively drug resistant. Previous treatment for TB was the strongest risk factor for MDR TB. High levels of primary transmission and advanced resistance to second-line drugs characterize MDR TB cases in Europe.</p></description>
</descriptions>
<formats>
<format>application/pdf</format>
</formats>
</resource>